Raymond James & Associates Axsome Therapeutics, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 8,701 shares of AXSM stock, worth $1.06 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,701
Previous 8,643
0.67%
Holding current value
$1.06 Million
Previous $695,000
12.37%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding AXSM
# of Institutions
403Shares Held
37.4MCall Options Held
507KPut Options Held
540K-
Vanguard Group Inc Valley Forge, PA3.95MShares$480 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$402 Million0.01% of portfolio
-
Bvf Inc San Francisco, CA1.69MShares$206 Million6.93% of portfolio
-
Rtw Investments, LP New York, NY1.52MShares$185 Million2.43% of portfolio
-
Macquarie Group LTD Australia, C31.14MShares$138 Million0.15% of portfolio
About Axsome Therapeutics, Inc.
- Ticker AXSM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,878,000
- Market Cap $5.22B
- Description
- Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...